Ironwood Pharmaceuticals, Inc. Share Price & Technical Analysis
IRWD · $3.90 (-0.51%)
Healthcare / Drug Manufacturers - Specialty & Generic
$3.90
-0.51%
Ironwood Pharmaceuticals, Inc., a biotechnology company, focuses on the development and commercialization of therapies for gastrointestinal (GI) and rare diseases in the United States and internationally. It sells linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation, as well a…
Price chart
Seasonality
May has 1 positive and 4 negative years (last 5 years shown)
-5% return in May, -16% avg return in past 3 year May month.
-9% return in 2026, -4% avg return in past 3 years.
Swipe sideways to see all months →
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Yr | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 | 7% | -31% | 6% | 14% | -5% | – | – | – | – | – | – | – | -9% |
| 25 | -49% | -27% | -6% | -40% | -33% | 17% | 14% | 63% | 0% | 46% | 75% | -3% | 56% |
| 24 | 26% | -34% | -6% | -9% | -19% | 5% | 5% | -26% | -18% | -2% | -12% | 26% | -67% |
| 23 | -7% | -1% | -6% | -1% | 5% | -3% | 5% | -21% | 9% | -6% | 11% | 15% | 0% |
| 22 | -5% | -3% | 17% | -6% | -5% | 2% | -1% | -4% | -3% | 5% | 10% | 2% | 10% |
Monthly return % by calendar month · historical pattern, not a forecast
Bearish · Emerging · Neutral
Ironwood Pharmaceuticals, Inc., a biotechnology company, focuses on the development and commercialization of therapies for gastrointestinal (GI) and rare diseases in the United States and internationally. It sells linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation, as well as for pediatric patients suffering from functional constipation under the LINZESS and CONSTELLA names. The company is also developing IW-3300, a GC-C agonist for the treatment of visceral pain conditions, including interstitial cystitis/bladder pain syndrome and endometriosis; and Apraglutide, a synthetic peptide long-acting analog of glucagon-like peptide-2 for short bowel syndrome patients dependent on parenteral support, as well as for acute graft versus host disease. It has strategic partnerships with AbbVie Inc., AstraZeneca AB, and Astellas Pharma Inc. for the development and commercialization of linaclotide. The company was formerly known as Microbia, Inc. and changed its name to Ironwood Pharmaceuticals, Inc. in April 2008. Ironwood Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Boston, Massachusetts.
Full AI Q&A, portfolio tracking, and live alerts in the app.
Key metrics
Market cap
$657.63M
P/E ratio
6.44
52W high
$5.78
52W low
$0.56
Volume
25,69,135
Beta
0.30
Related stocks in Healthcare
Merck & Co Inc Cedear (5…
₹32,900
Abbott Laboratories Cede…
₹30,500
Eli Lilly And Company Ce…
₹25,540
Unitedhealth Group Inc C…
₹17,200
₹6,600
Frequently asked questions
- What is Ironwood Pharmaceuticals, Inc. share price today?
- Ironwood Pharmaceuticals, Inc. (IRWD) last traded around $3.90 on StockPro. Prices refresh every few minutes during market hours.
- What technical signals does IRWD have?
- StockPro monitors breakouts, volume spikes, EMA reversals, and momentum for IRWD. Download the app for real-time alerts.
- How can I analyze Ironwood Pharmaceuticals, Inc. stock?
- Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.